Investigational drug · Phase 3
OLN324
Not approved by FDA. In 4 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Diabetic Macular Edema (DME), Wet Age Related Macular Degeneration, Wet Age-related Macular Degeneration.
Phase 3Last checked: Nov 19, 2026Latest source record: Sep 25, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
4
4 still active
All registered trials
5
Any phase or sponsor naming "OLN324"
First trial start
2026
Oct 15, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "OLN324", any sponsor or status.
Conditions studied
As listed on its trial records.
- Diabetic Macular Edema (DME)
- Wet Age Related Macular Degeneration
- Wet Age-related Macular Degeneration
Approved drugs for the same conditions: Wet macular degeneration · Diabetic macular edema · Cardiovascular and metabolic · Ophthalmology
Largest trials
Live from ClinicalTrials.gov: studies naming "OLN324" as an intervention, largest first.
- Phase 3 Study of Intravitreal OLN324 in Adults With Neovascular (Wet) Age-related Macular Degeneration (nAMD) (OLN324-CP-04)Pivotal-lookingNot yet recruiting
Ollin Biosciences, Inc.Industry
NCT07816315 · 500 participants (planned) · Start Oct 15, 2026 · Primary completion Dec 15, 2028
Drug: OLN324; Aflibercept · For: Wet Age Related Macular Degeneration
- Phase 3 Study of Intravitreal OLN324 in Adults With Diabetic Macular Edema (DME) (OLN324-CP-03)Pivotal-lookingNot yet recruiting
Ollin Biosciences, Inc.Industry
NCT07842016 · 450 participants (planned) · Start Oct 15, 2026 · Primary completion Dec 15, 2028
Drug: OLN324; Aflibercept · For: Diabetic Macular Edema (DME)
- Phase 3 Study of Intravitreal OLN324 in Adults With Diabetic Macular Edema (DME) (OLN324-CP-02)Pivotal-lookingNot yet recruiting
Ollin Biosciences, Inc.Industry
NCT07841899 · 450 participants (planned) · Start Oct 15, 2026 · Primary completion Dec 15, 2028
Drug: OLN324; Aflibercept · For: Diabetic Macular Edema (DME)
- Phase 3 Study of Intravitreal OLN324 in Adults With Neovascular (Wet) Age-related Macular Degeneration (nAMD) (OLN324-CP-05)Pivotal-lookingNot yet recruiting
Ollin Biosciences, Inc.Industry
NCT07816289 · 400 participants (planned) · Start Oct 15, 2026 · Primary completion Dec 15, 2028
Drug: OLN324; Ranibizumab · For: Wet Age-related Macular Degeneration
- A Phase 1b Study to Assess the Safety, Tolerability, Pharmacokinetics, and Exploratory Efficacy of Intravitreal OLN324Pivotal-lookingCompleted
Ollin Biosciences, Inc.Industry
NCT07484074 · 164 participants · Start Feb 12, 2025 · Primary completion Oct 10, 2025
Drug: Faricimab; OLN324 · For: Diabetic Macular Edema (DME); Neovascular (Wet) Age-Related Macular Degeneration
Sites: Phoenix, Arizona; Glendale, California; Pasadena, California · 30 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Diabetic Macular Edema (DME)
- 4D-1503E10 vg, eyePhase 35 trials
4D Molecular Therapeutics · Neovascular Age-Related Macular Degeneration (nAMD), Diabetic Macular Edema (DME), Neovascular (Wet) Age-Related Macular Degeneration
- TiespectusEYE201, MK-8748Phase 35 trials
EyeBiotech Ltd. · Macular Degeneration, Age-Related Macular Degeneration, Choroidal Neovascularization
- EYP-1901Phase 34 trials
EyePoint Pharmaceuticals, Inc. · Diabetic Macular Edema, DME, Diabetic Macular Edema (DME)
- RemigromigEYE103, RestoretPhase 33 trials
EyeBiotech Ltd. · Diabetic Macular Edema (DME), Neovascular Age-Related Macular Degeneration (NVAMD), Branch Retinal Vein Occlusion (BRVO)
- BAT5906Phase 32 trials
Bio-Thera Solutions · Diabetic Macular Edema (DME), Neovascular (Wet) Age-related Macular Degeneration
- Tabirafusp tedromerKSI-501Phase 32 trials
Kodiak Sciences Inc · Diabetic Macular Edema (DME), Wet Age-related Macular Degeneration
- RC28-EPhase 31 trial
RemeGen Co., Ltd. · Diabetic Macular Edema (DME), wAMD
- BGE-102Phase 22 trials
BioAge Labs, Inc. · Diabetic Macular Edema (DME), Obesity and Cardiovascular Risk
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.